arthritis

1
CelecoxCur
A New Discovery in Nanomedicine
CelecoxCur

• A Safe And Fffective Nanomedicine For Arthritis

2

New Discovery New Treatment
1
2
3
A new approach to treat Arthritis
4
CELECOXCUR

• Discovery leads to develop a potentiating hybrid
  drug for Arthritic pain
• The CELECOXCUR-Nanomedicine

LOW DOSE BY IMPROVING SOLUBILITY MAY ANSWER TO
MANY PROBLEMS
3
PROBLEM

• Although a wide range of drugs are available, the
  successful and cost effective treatment of
  inflammatory arthritis is still a major unmet
  medical need
• Celecoxib is not readily dissolved and dispersed
  for rapid absorption in the gastrointestinal
  tract when administered orally
• More generally, a need exists for orally
  deliverable formulations of cyclooxygenase-2
  inhibitory drugs of low water solubility
  including celecoxib. Hence to use high dose to
  achieve the required efficacy
• Do we need to use 400mg of Celecoxib?
• Is the drug is a problem or the dosage ?
• Patent expired hence a threat to sale.

The FDA committee advised doctors to prescribe
the lowest available doses of Celebrex (200
mg/day) and Bextra (10 mg/day). But how sure are
we that these dosages are safe? We know that 400
mg/day of Celebrex causes heart attacks and
strokes can we be sure that 200 mg doesn't? We
know that 20 mg/day of Bextra causes heart
attacks and strokes can we be sure that 10 mg
doesn't? No, we cannot be sure. More likely, even
at these lower recommended dosages, some risk
remains.
4
OPPORTUNITY
5
TNF
Phospholipid
PLA2G2A
PLA2G4A
NF-kB
IL6
arachidonic acid
PTGS2
CelecoxCur
PTGS1
IL6
PGH2
?????
PGD2
PGI2
PGD2
Inflammation Pain Fever Neoplasia Cytoprotection
PGI2
PGD2
Allergy Aasthma
Platelet Aggregation Vasoconstriction
6
FUNDS

• 1M INVESTED
• 3M NEEDED ( FOR ANALYTICAL TOOL, cGMP
  MANUFACTURING, PRE-CLINICAL, IND, etc)

7
PROGRESS

• PROOF OF CONCEPT ------------------
  ESTABLISHED
• R D----------------------------------------
  -MOSTLY ESTABLISHED
• PILOT SCALE MANUFACTURING---- ESTABLISHED
• IN-VITRO STUDY----------------------- -
  PRELIMINARY TESTING
• Pilot scale Production-------------------
  Established
• ANIMAL STUDIES-----------------------
  ON-GOING

8
Discovery/ Answer to Problem

• CELECOXCUR IS A HYBRID DRUG OF TWO MOLECULES
• CELECOXCUR IS WATER SOLUBLE (BIOAVAILABLE)
• CELECOXCUR IS SAFE FOR STOMACH
• CELECOXCUR IS PATENTED
• CELECOXCUR IS MORE POTENT
• CELECOXCUR IS NEW APPROACH
• CELECOXCUR WATER SOLUBILITY PROBLEM RESOLVED
• CELECOXCUR LOW DOSE TO ACHIEVE THE SAME RESULTS
  AS OF 400MG OF CELECOXIB
• No SDS, No T-20, No oil, No alcohol, No casein,
  No cellulose, No PEF and No lipid in CelecoxCur

The present invention of CELECOXCUR is directed
to a method of treating inflammatory arthritis in
a cost effective manner BY LOW DOSE AND LOW COST
OF MANUFACTURING. SHOULD BE FAFFER.
9
MILESTONES

• cGMPManufacturing (1st year)
• Animal efficacy Drug Interactions (1st year)
• IND (2nd year)
• Phase I (2nd year)
• Phase II (3rd year)
• License submission (3rd and 4th year)

10
SAFE AND MORE POTENT
It is not micro It is Nano NO OIL, No
detergent IT IS MORE POTENT LESS TOXIC AND COST
EFFECTIVE ACT ON MULTIPLE SITE
Nanomedicine is The Answer
11
Need

• Looking for partnership for product development
• Looking for VC to develop product
• Collaboration with generic companies
• We provide patent protection
• We provide branding
• Protection from generic cliff

12
(No Transcript)
13
CONTACT
Join us to take this Discovery to clinic

• Mewa Singh, PhD
• 609-902-7128
• mewasinghsandhu_at_hotmail.com
• www.nanomeda.com
• www.nanosgroup.com

Nanomedicine Is The Future Of Pharma